{"entity":{"id":"sevilla","kind":"trial","name":"SEVILLA","aka":[],"tldr":"SEVILLA is a French-British randomised trial comparing ivonescimab, an antibody that blocks both PD-1 and the blood vessel signal VEGF, with FOLFOX chemotherapy as second-line treatment for bile duct and gallbladder cancer. University College London is the UK site.","summary":"SEVILLA (NCT06529718) is a randomised phase 2 run by UNICANCER at 42 sites in France and the United Kingdom, open since October 2025 with 72 patients planned and primary completion listed for August 2027. Eligible patients have histologically proven intrahepatic, perihilar or distal cholangiocarcinoma or gallbladder carcinoma (ampullary carcinoma excluded) that has progressed after first-line treatment, and are randomised to the PD-1 and VEGF bispecific antibody ivonescimab or to FOLFOX, the ABC-06 standard. The primary endpoint is progression-free survival. It is one of the first trials to test a bispecific immunotherapy against chemotherapy in second-line biliary cancer and gives UK patients with gallbladder cancer a randomised second-line option.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06529718","url":"https://clinicaltrials.gov/study/NCT06529718"}],"tags":[],"related":[],"cancers":["gallbladder","cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":["pd1","vegf"],"drugs":["ivonescimab","folfox"],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (1, registry): University College London (London)."],"nct":"NCT06529718","phase":"2","setting":"Second-line locally advanced or metastatic biliary cancer (intrahepatic, perihilar or distal cholangiocarcinoma, or gallbladder carcinoma; ampullary excluded): ivonescimab versus FOLFOX, randomised, primary endpoint progression-free survival","sponsor":"UNICANCER","enrolled":72,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/sevilla/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"institution":[{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}